Press Room

Press Release / Jan 20, 2026

Hovione’s people-first approach recognized as it achieves Top Employer certification for the fourth consecutive year

Hovione has achieved Top Employer certification across all four of its manufacturing sites worldwide for the fourth consecutive year.

Hovione is Top Employer 2026 4th consecutive year | Hovione
  • Top Employer certification applies across all of Hovione’s manufacturing sites in Portugal, the US, Ireland and China
  • Certification highlights significant progress made by Hovione in these key areas: Employer Branding, Digital HR, DEI, Leadership, Learning, Sustainability, Well-being, and Work Environment
     

Lisbon, Portugal, January 15, 2026 - Hovione, an international integrated pharmaceutical development and manufacturing organization, has achieved Top Employer certification across all four of its manufacturing sites worldwide for the fourth consecutive year. 

A globally recognized certification, the Top Employers Institute acknowledges excellence in people practices. With over 2,500 employees globally in New Jersey (US), Cork (Ireland), Lisbon (Portugal), and Macau (China), this certification is a testament to Hovione’s commitment to continually creating a working environment for its team that prioritizes employee well-being, nurtures talent, and values and rewards merit and dedication. 

Talent acquisition and retention remain challenging in the pharmaceutical industry, but Hovione has successfully bucked this trend with an historic lower-than-industry-average voluntary staff turnover rate. The firm continuously strives to refine its working practices to foster employee motivation and satisfaction. It has also developed a culture where individual contributions are valued and rewarded, aligning with the company’s overall success.  

“Our people-first approach has once again been recognized”, said Dr. Jean-Luc Herbeaux, Chief Executive Officer, Hovione. “This is a reflection of the commitment and dedication that has gone into creating a working environment across all of our sites where our team members are empowered to perform at their best every day.”

“At Hovione, our people agenda is not solely an HR topic - it is a core pillar of our strategy to be a differentiated and enabling partner to the pharmaceutical industry. We invest continuously to create the best possible environment for our teams to do great work. And when this is combined with the deeper purpose behind what we do, helping to develop and manufacture life-enhancing medicines, it creates a powerful engine for innovation, differentiation, and growth, where all stakeholders are rewarded.”

A key area recognized by The Top Employer’s Institute this time was Hovione’s best practice approach to sustainability, with the firm demonstrating that it has successfully cultivated a culture of responsibility, collaboration, and continuous improvement in this area. The company´s efforts to prioritize equity and inclusion were also acknowledged, helping strengthen its differentiated Employee Value Proposition, and enriching the journey for both current and future talent. 
Ilda Ventura, Senior Vice-President of Human Resources and Member of the Management Board, Hovione, said: “Benchmarking our people practices as part of the Top Employers certification process tells us that we’re on the right track.”

“Receiving the Top Employers certification for the fourth consecutive year reflects our continued commitment and efforts to putting people at the center of our business. By designing inclusive and consistent HR practices across all locations, we continue to bolster our Employee Value Proposition and create a workplace where talent can grow, engage, and succeed.”

 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026